Determination of Vancomycin in Human Plasma, Bone and Fat by Liquid Chromatography/Tandem Mass SpectrometryMei Zhang1,2*, Grant A Moore2 and Simon W Young3
- *Corresponding Author:
- Dr. Mei Zhang
Clinical Pharmacology, Department of Medicine
University of Otago - Christchurch/ Toxicology
Canterbury Health Laboratories, Christchurch, New Zealand
Tel: 0064 3 364 0640 ext 89746
Fax: 0064 3 364 1003
E-mail: [email protected]
Received date: June 27, 2014; Accepted date: July 16, 2014; Published date: July 18, 2014
Citation: Zhang M, Moore GA, Young SW (2014) Determination of Vancomycin in Human Plasma, Bone and Fat by Liquid Chromatography/Tandem Mass Spectrometry. J Anal Bioanal Tech 5: 196. doi: 10.4172/2155-9872.1000196
Copyright: © 2014 Zhang M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay was developed for the determination of vancomycin in human plasma, bone and fat tissue. For vancomycin in plasma, sample was treated with methanol to precipitate the proteins. After centrifugation, the supernatant was diluted with water, and then injected into the LC-MS/MS system. For vancomycin in bone and fat, the pulverized bone/fat samples were immersed in phosphate buffered saline pH 7.3 at 4°C overnight. After centrifugation, the supernatant of bone/fat tissue suspension was treated in the same way as the plasma samples. Vancomycin and aminopterin, the internal standard, were resolved on a C18(2) column using gradient elution of 0.05% formic acid and methanol. The two compounds were detected using electrospray ionisation in the positive mode. Standard curves were linear over the concentration range 0.05 to 50 mg/L (r2>0.99) in plasma, bone and fat. Bias was ≤ ± 10% from 0.05 to 50 mg/L, intra- and inter-day coefficients of variation (imprecision) were <10%, and the limit of quantification was 0.05 mg/L. The assay has been used successfully in a clinical study to investigate the regional delivery of vancomycin in bone and fat after prophylactic administration of vancomycin through an intraosseous route or systemic route, during total knee arthroplasty.